help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Plouin, P.-F.
Right arrow Articles by Chatellier, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Plouin, P.-F.
Right arrow Articles by Chatellier, G.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Pheochromocytoma
The Journal of Clinical Endocrinology & Metabolism Vol. 86, No. 4 1480-1486
Copyright © 2001 by The Endocrine Society


Special Articles

Factors Associated with Perioperative Morbidity and Mortality in Patients with Pheochromocytoma: Analysis of 165 Operations at a Single Center1

Pierre-François Plouin, Jean-Marc Duclos, Frederique Soppelsa, Gaetan Boublil and Gilles Chatellier

Departments of Hypertension, Urology, and Medical Informatics, Hôpital Broussais-Saint Joseph, 75908 Paris Cedex 15; and Gestion Essais Cliniques, Etudes Statistiques Monitoring, 92120 Montrouge, France

Address all correspondence and requests for reprints to: Dr. Pierre-François Plouin, Hypertension Unit, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75908 Paris Cedex 15, France. E-mail: pierre-francois.plouin{at}egp.ap-hop-paris.fr

To identify preoperative factors associated with 30-day morbidity and mortality after pheochromocytoma surgery, we carried out an external review of the records of all patients undergoing pheochromocytoma surgery from 1975 to 1997 at a single center. One hundred and forty-seven patients, including 23 with malignant tumors at the time of the first operation, underwent 165 operations. Death, resection of a neighboring organ, further surgery, secondary transfer to an intensive care unit, and any events associated with a surgical stay exceeding 10 days were defined as complications. Mortality and morbidity were 4 of 165 (2.4%) and 38 of 161 (23.6%), respectively. Morbidity included 13 spleen resections and hematomas. Spleen complications were not related to tumor location, but were probably due to the operative strategy used, a transperitoneal complete abdominal exploration including both adrenal glands. Complications were independently associated with preoperative systolic blood pressure [odds ratio (OR), 1.14/cm Hg], urinary metanephrine excretion (OR, 1.18/10 µmol·day), and with the number of operations (repeat vs. first operation OR, 5.36). In conclusion, pheochromocytoma resection consistently involves a risk of complications. Spleen damage should be prevented by complete preoperative localization studies and an elective or laparoscopic surgical approach. Careful blood pressure control should help prevent complications. Patients with high secretion tumors and those undergoing repeat intervention are at high risk of complications and should be referred to centers familiar with pheochromocytoma management.




This article has been cited by other articles:


Home page
The OncologistHome page
J. T. Adler, G. Y. Meyer-Rochow, H. Chen, D. E. Benn, B. G. Robinson, R. S. Sippel, and S. B. Sidhu
Pheochromocytoma: Current Approaches and Future Directions
Oncologist, July 1, 2008; 13(7): 779 - 793.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
D. Pasquali, V. Rossi, G. Conzo, G. Pannone, P. Bufo, A. De Bellis, A. Renzullo, G. Bellastella, A. Colao, G. Vallone, et al.
Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells
J. Mol. Endocrinol., June 1, 2008; 40(6): 263 - 271.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
K. Pacak
Preoperative Management of the Pheochromocytoma Patient
J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4069 - 4079.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
N. S. Tarant, R. G. Dacanay, B. W. Mecklenburg, S. D. Birmingham, E. Lujan, and R. Green
Acute Appendicitis in a Patient with Undiagnosed Pheochromocytoma
Anesth. Analg., February 1, 2006; 102(2): 642 - 643.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
K. O. Rynn, F. L. Hughes, and B. Faley
An Emergency Department Approach to Drug Treatment of Hypertensive Urgency and Emergency
Journal of Pharmacy Practice, October 1, 2005; 18(5): 363 - 376.
[Abstract] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. Amar, A. Servais, A.-P. Gimenez-Roqueplo, F. Zinzindohoue, G. Chatellier, and P.-F. Plouin
Year of Diagnosis, Features at Presentation, and Risk of Recurrence in Patients with Pheochromocytoma or Secreting Paraganglioma
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2110 - 2116.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
J. Favier, P.-F. Plouin, P. Corvol, and J.-M. Gasc
Angiogenesis and Vascular Architecture in Pheochromocytomas : Distinctive Traits in Malignant Tumors
Am. J. Pathol., October 1, 2002; 161(4): 1235 - 1246.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
Q.-Y. Duh
Editorial: Evolving Surgical Management for Patients with Pheochromocytoma
J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1477 - 1479.
[Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2001 by The Endocrine Society